Published in Arch Intern Med on May 14, 2007
Effect of Phosphorus Additives on the Metabolome in Healthy Adults | NCT03841786
25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med (2008) 9.50
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol (2009) 2.71
High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr (2013) 2.66
Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol (2008) 2.65
Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol (2011) 2.59
Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res (2011) 2.56
Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis (2008) 2.46
Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol (2008) 2.32
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol (2008) 2.18
Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol (2009) 2.09
Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis (2011) 1.83
Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis (2010) 1.82
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int (2012) 1.82
Con: Phosphate binders in chronic kidney disease. Nephrol Dial Transplant (2015) 1.72
Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol (2009) 1.67
Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol (2013) 1.66
Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. Clin J Am Soc Nephrol (2009) 1.62
Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke (2011) 1.57
Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol (2010) 1.53
Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study. Kidney Int (2016) 1.52
Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant (2009) 1.51
Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J (2011) 1.49
Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr (2012) 1.46
Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol (2010) 1.46
Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol (2009) 1.39
Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol (2010) 1.35
Phosphate additives in food--a health risk. Dtsch Arztebl Int (2012) 1.33
The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis (2011) 1.26
Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene. PLoS Genet (2010) 1.25
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol (2010) 1.21
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
Common genetic variants associate with serum phosphorus concentration. J Am Soc Nephrol (2010) 1.20
Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.20
Dietary phosphorus, blood pressure, and incidence of hypertension in the atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. Hypertension (2010) 1.18
Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey. J Ren Nutr (2010) 1.18
Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis (2011) 1.17
Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol (2011) 1.16
Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol (2008) 1.16
Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant (2011) 1.14
Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol (2011) 1.14
Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho). Best Pract Res Clin Rheumatol (2011) 1.13
Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail (2010) 1.13
FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med (2014) 1.09
Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07
Artificial receptors for the recognition of phosphorylated molecules. Chem Rev (2011) 1.06
Phosphate and cardiovascular disease. Adv Chronic Kidney Dis (2011) 1.06
Phosphate is a vascular toxin. Pediatr Nephrol (2012) 1.05
Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail (2011) 1.05
Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol (2013) 1.04
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol (2013) 1.03
Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol (2011) 1.02
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol (2014) 1.01
Mechanisms and clinical consequences of vascular calcification. Front Endocrinol (Lausanne) (2012) 1.01
Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr (2014) 1.00
Assessing the health impact of phosphorus in the food supply: issues and considerations. Adv Nutr (2014) 0.99
Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence (2013) 0.99
Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One (2013) 0.99
An integrated understanding of the physiological response to elevated extracellular phosphate. J Cell Physiol (2013) 0.98
Prevalence and prognostic significance of renal artery calcification in patients with diabetes and proteinuria. Clin J Am Soc Nephrol (2010) 0.97
Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study. Am J Kidney Dis (2012) 0.96
Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol (2010) 0.95
Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol (2012) 0.95
Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol (2010) 0.95
Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int Suppl (2011) 0.94
Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost (2010) 0.94
Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Ren Nutr (2012) 0.94
Intestinal phosphate transport. Adv Chronic Kidney Dis (2011) 0.94
Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study. Kidney Int (2010) 0.93
Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. Am J Epidemiol (2010) 0.93
Vitamin D, calcium, and atherosclerotic risk: evidence from serum levels and supplementation studies. Curr Atheroscler Rep (2013) 0.93
Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study). Am J Cardiol (2012) 0.93
Bone mineral metabolism and subsequent hospitalization with poor quality of life in dialysis patients. Nephrourol Mon (2014) 0.92
NHE3 regulatory factor 1 (NHERF1) modulates intestinal sodium-dependent phosphate transporter (NaPi-2b) expression in apical microvilli. J Biol Chem (2012) 0.92
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol (2012) 0.92
Mineral (Mal)Adaptation to Kidney Disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol (2015) 0.91
Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). Am J Cardiol (2010) 0.91
Inorganic phosphate and the risk of cancer in the Swedish AMORIS study. BMC Cancer (2013) 0.90
Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrol Dial Transplant (2011) 0.90
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Coronary artery calcification in chronic kidney disease: An update. World J Cardiol (2014) 0.88
Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study. Am J Kidney Dis (2010) 0.87
Association of a reduction in central obesity and phosphorus intake with changes in urinary albumin excretion: the PREMIER study. Am J Kidney Dis (2013) 0.87
Biochemical markers of aging for longitudinal studies in humans. Epidemiol Rev (2013) 0.87
The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know. Adv Nutr (2013) 0.87
Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Nutrients (2013) 0.87
Can features of phosphate toxicity appear in normophosphatemia? J Bone Miner Metab (2012) 0.86
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol (2014) 0.86
24-hour urine phosphorus excretion and mortality and cardiovascular events. Clin J Am Soc Nephrol (2013) 0.86
Phosphorus is associated with coronary artery disease in patients with preserved renal function. PLoS One (2012) 0.85
Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing. Nephrol Dial Transplant (2014) 0.85
Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study. Eur J Epidemiol (2013) 0.85
The relation between serum phosphorus levels and clinical outcomes after acute myocardial infarction. PLoS One (2013) 0.85
Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia (2014) 0.84
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension (2004) 8.27
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Aortic stiffness, blood pressure progression, and incident hypertension. JAMA (2012) 6.01
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75